Jaume Pons, ALX Oncology CEO
Betting on CD47 as others ditch the target, ALX borrows up to $100M to push sole clinical drug forward
At its peak, ALX Oncology $ALXO was trading at $88 per share, riding on the promise of blocking CD47, which cancer cells use to broadcast …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
